Importance: Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for colorectal polyps and cancer. A combination of sulindac and erlotinib led to a 71% reduction in duodenal polyp burden in a phase 2 trial. Objective: To evaluate effect of sulindac and erlotinib on colorectal adenoma regression in patients with FAP. Design, Setting, and Participants: Prespecified secondary analysis for colorectal adenoma regression was carried out using data from a double-blind, randomized, placebo-controlled trial, enrolling 92 patients with FAP, conducted from July 2010 to June 2014 in Salt Lake City, Utah. Interventions: Patients were randomized to sulindac, 150 mg twice daily, and erlotinib, 75 mg daily (n = 46), vs placebo (n = 46) for 6 months. Main Outcomes and Measurements: The total number of polyps in the intact colorectum, ileal pouch anal anastomosis, or ileo-rectum were recorded at baseline and 6 months. The primary outcomes were change in total colorectal polyp count and percentage change in colorectal polyps, following 6 months of treatment. Results:Eighty-two randomized patients (mean [SD] age, 40 [13] years; 49 [60%] women) had colorectal polyp count data available for this secondary analysis: 22 with intact colon, 44 with ileal pouch anal anastomosis and 16 with ileo-rectal anastomosis; 41 patients receivedsulindac/erlotinib and 41 placebo. The total colorectal polyp count was significantly different between the placebo and sulindac-erlotinib group at 6 months in patients with net percentage change of 69.4% in those with an intact colorectum compared with placebo (95% CI, 28.8%-109.2%; P = .009). Conclusion and Relevance: In this double-blind, placebo-controlled, randomized trial we showed that combination treatment with sulindac and erlotinib compared with placebo resulted in significantly lower colorectal polyp burden after 6 months of treatment. There was a reduction in polyp burden in both those with an entire colorectum and those with only a rectal pouch or rectum. Trial Registration: clinicaltrials.gov Identifier: NCT01187901.
RCT Entities:
Importance: Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for colorectal polyps and cancer. A combination of sulindac and erlotinib led to a 71% reduction in duodenal polyp burden in a phase 2 trial. Objective: To evaluate effect of sulindac and erlotinib on colorectal adenoma regression in patients with FAP. Design, Setting, and Participants: Prespecified secondary analysis for colorectal adenoma regression was carried out using data from a double-blind, randomized, placebo-controlled trial, enrolling 92 patients with FAP, conducted from July 2010 to June 2014 in Salt Lake City, Utah. Interventions: Patients were randomized to sulindac, 150 mg twice daily, and erlotinib, 75 mg daily (n = 46), vs placebo (n = 46) for 6 months. Main Outcomes and Measurements: The total number of polyps in the intact colorectum, ileal pouch anal anastomosis, or ileo-rectum were recorded at baseline and 6 months. The primary outcomes were change in total colorectal polyp count and percentage change in colorectal polyps, following 6 months of treatment. Results: Eighty-two randomized patients (mean [SD] age, 40 [13] years; 49 [60%] women) had colorectal polyp count data available for this secondary analysis: 22 with intact colon, 44 with ileal pouch anal anastomosis and 16 with ileo-rectal anastomosis; 41 patients received sulindac/erlotinib and 41 placebo. The total colorectal polyp count was significantly different between the placebo and sulindac-erlotinib group at 6 months in patients with net percentage change of 69.4% in those with an intact colorectum compared with placebo (95% CI, 28.8%-109.2%; P = .009). Conclusion and Relevance: In this double-blind, placebo-controlled, randomized trial we showed that combination treatment with sulindac and erlotinib compared with placebo resulted in significantly lower colorectal polyp burden after 6 months of treatment. There was a reduction in polyp burden in both those with an entire colorectum and those with only a rectal pouch or rectum. Trial Registration: clinicaltrials.gov Identifier: NCT01187901.
Authors: Nadir Arber; Craig J Eagle; Julius Spicak; István Rácz; Petr Dite; Jan Hajer; Miroslav Zavoral; Maria J Lechuga; Paola Gerletti; Jie Tang; Rebecca B Rosenstein; Katie Macdonald; Pritha Bhadra; Robert Fowler; Janet Wittes; Ann G Zauber; Scott D Solomon; Bernard Levin Journal: N Engl J Med Date: 2006-08-31 Impact factor: 91.245
Authors: R J Coffey; C J Hawkey; L Damstrup; R Graves-Deal; V C Daniel; P J Dempsey; R Chinery; S C Kirkland; R N DuBois; T L Jetton; J D Morrow Journal: Proc Natl Acad Sci U S A Date: 1997-01-21 Impact factor: 11.205
Authors: Patrick M Lynch; Gregory D Ayers; Ernie Hawk; Ellen Richmond; Craig Eagle; Mabel Woloj; James Church; Hennie Hasson; Sherri Patterson; Elizabeth Half; Carol A Burke Journal: Am J Gastroenterol Date: 2010-03-16 Impact factor: 10.864
Authors: Reade B Roberts; Lu Min; M Kay Washington; Sandra J Olsen; Stephen H Settle; Robert J Coffey; David W Threadgill Journal: Proc Natl Acad Sci U S A Date: 2002-01-29 Impact factor: 11.205
Authors: Annie L Eisinger; Lincoln D Nadauld; Dawne N Shelton; Peter W Peterson; Reid A Phelps; Stephanie Chidester; Diana M Stafforini; Stephen M Prescott; David A Jones Journal: J Biol Chem Date: 2006-05-14 Impact factor: 5.157
Authors: J Groden; A Thliveris; W Samowitz; M Carlson; L Gelbert; H Albertsen; G Joslyn; J Stevens; L Spirio; M Robertson Journal: Cell Date: 1991-08-09 Impact factor: 41.582
Authors: Thomas J Lynch; David Fenton; Vera Hirsh; David Bodkin; Edward L Middleman; Alberto Chiappori; Balazs Halmos; Reyna Favis; Hua Liu; William L Trepicchio; Omar Eton; Frances A Shepherd Journal: J Thorac Oncol Date: 2009-08 Impact factor: 15.609
Authors: F M Giardiello; S R Hamilton; A J Krush; S Piantadosi; L M Hylind; P Celano; S V Booker; C R Robinson; G J Offerhaus Journal: N Engl J Med Date: 1993-05-06 Impact factor: 91.245
Authors: Sai Ge; Duo Cheng; Xuhui Zhang; Ting Xu; Zhenghang Wang; Fengxiao Dong; Lan Su; Jinlei Song; Jia Wang; Jian Li; Lin Shen; Xicheng Wang Journal: Am J Cancer Res Date: 2022-09-15 Impact factor: 5.942
Authors: Antonio V Sterpetti; Umberto Costi; Raffaele Grande; Giuseppe D'Ermo; Paolo Sapienza Journal: Ann Surg Oncol Date: 2020-03-05 Impact factor: 5.344
Authors: Ahmet M Ulusan; Praveen Rajendran; Wan Mohaiza Dashwood; Omer F Yavuz; Sabeeta Kapoor; Trace A Gustafson; Michelle I Savage; Powel H Brown; Shizuko Sei; Altaf Mohammed; Eduardo Vilar; Roderick H Dashwood Journal: Cancer Prev Res (Phila) Date: 2020-12-04
Authors: Charles M Bowen; Lewins Walter; Ester Borras; Wenhui Wu; Zuhal Ozcan; Kyle Chang; Prashant V Bommi; Melissa W Taggart; Selvi Thirumurthi; Patrick M Lynch; Laura Reyes-Uribe; Paul A Scheet; Krishna M Sinha; Eduardo Vilar Journal: Cancer Prev Res (Phila) Date: 2021-07-15